Prostaglandin receptor EP2 antagonists, derivatives, compositions, and uses related thereto
The disclosure relates to Prostaglandin receptor EP2 antagonists, derivatives, compositions, and methods related thereto. In certain embodiments, the disclosure relates to methods of treating or preventing conditions and diseases in which EP2 receptor activation has a physiological role, such as but not limited to, brain injury, inflammatory diseases, neuroinflammation after a seizure, pain, endometriosis, cancer, rheumatoid arthritis, skin inflammation, vascular inflammation, colitis, and neurological disorders by administering a pharmaceutical composition comprising a compound disclosed herein to a subject in need thereof.
1. A method of treating endometriosis comprising administering an effective amount of N-(2-(2-methyl-1H-indol-3-yl)ethyl)-4-(1H-tetrazol-5-yl)benzamide or salt thereof to a subject in need thereof.
2. A method of treating arthritis comprising administering an effective amount of N-(2-(2-methyl-1H-indol-3-yl)ethyl)-4-(1H-tetrazol-5-yl)benzamide or salt thereof to a subject in need thereof.
3. The method of claim 2 , wherein the arthritis is rheumatoid arthritis, enthesitis-related arthritis, or psoriatic arthritis.
4. A method of treating cancer comprising administering an effective amount of N-(2-(2-methyl-1H-indol-3-yl)ethyl)-4-(1H-tetrazol-5-yl)benzamide or salt thereof to a subject in need thereof.
5. The method of claim 4 wherein the cancer is skin, blood vessel, lung, head, neck, prostate, colon, ovary, or breast cancer.
6. The method of claim 4 wherein the cancer is hepatocellular carcinoma.